Previous 10 | Next 10 |
Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020 compared to the 16% in the SPDR S&P 500 Trust ETF (SPY). The outlook is underpinned by uncertainty...
Iovance is ramping up tumor-infiltrating lymphocytes as an ingenious way to eradicate cancers. As such, I believe it'll continue to deliver stellar data. Riding robust data, LPN-145 and lifileucel, are advancing rapidly in development to serve unmet needs for various cancers. As I...
SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Maria Fardis, PhD, MBA, President and Chief Executive Officer of Iovance, plans t...
Iovance Biotherapeutics (IOVA) has appointed Jean-Marc Bellemin as CFO, effective today. Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics said, “Jean-Marc has extensive experience as a CFO in public biopharma companies with commercial products ...
SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Jean-Marc Bellemin as Chief Financial Officer, effective today. Mr....
ARKG aims to capitalize on a $9Tn TAM with the convergence of AI, DNA Sequencing and Gene-Editing. ARKG is up 149% YTD vs. the SPX return of 13%. Led by Cathie Wood, I think ARKG will be the best performing ARK Fund over the next 10 years. For further details see: ARKG: ...
The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companie...
SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November: ...
44.4% Overall Response Rate (ORR) and Median Duration of Response (DOR) Not Reached at 8.6 Months of Study Follow Up First Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy in Combination with Pembrolizumab SAN CARLOS, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Iovance ...
Iovance Biotherapeutics, Inc. (IOVA) Q3 2020 Earnings Conference Call November 05, 2020, 16:30 ET Company Participants Sara Pellegrino - VP, IR & Public Relations Maria Fardis - CEO, President & Director Friedrich Finckenstein - Chief Medical Officer Michael Swartzburg - VP, Finance a...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL recommendation for IOVA on July 29, 2024 02:11AM ET. The previous analyst recommendation was Overweight. IOVA was trading at $9.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-29 05:00:08 ET Joseph Catanzaro from Piper Sandler issued a price target of $10.00 for IOVA on 2024-07-29 02:11:00. The adjusted price target was set to $10.00. At the time of the announcement, IOVA was trading at $9.25. The overall price target consensus is at $...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...